<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585233</url>
  </required_header>
  <id_info>
    <org_study_id>7163-CL-0107</org_study_id>
    <nct_id>NCT01585233</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety and tolerability of multiple doses of
      ASKP1240 compared to placebo and determine Pharmacokinetics and Pharmacodynamics in subjects
      with moderate to severe psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with ASKP1240 or placebo will be over 4 weeks (Baseline/Day 1, Days 15 and Day 29)
      with 12 weeks of follow-up for a total of 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of ASKP1240: Area under the curve 0-336 (AUC336 )</measure>
    <time_frame>Day 1 to Day 113 (12 visits)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASKP1240: Maximum Concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 113 (12 visits)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic variable: CD40 receptor occupancy on peripheral blood B cells</measure>
    <time_frame>Day 1 to Day 113 (12 visits)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize safety profile of ASKP1240 through adverse event reporting, vital signs, clinical laboratory evaluations, physical examinations and 12-lead electrocardiograms (ECGs)</measure>
    <time_frame>113 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 8 weeks in Psoriasis Area Severity Index (PASI) score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 8 weeks in Physicians Static Global Assessment (PSGA) score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Treatment Success</measure>
    <time_frame>8 weeks</time_frame>
    <description>Success of the treatment of psoriasis is defined as a score of 1 (almost clear) or 0 (clear) as measured by the PSGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 8 weeks in % Body Surface Area (BSA)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Concentration</measure>
    <time_frame>Day 1 to Day 113 (9 visits)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-ASKP1240 antibodies</measure>
    <time_frame>Day 1 to Day 113 (8 visits )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte subset quantitation</measure>
    <time_frame>Day 1 to Day 113 (9 visits)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASKP1240 lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASKP1240 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASKP1240 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASKP1240 highest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASKP1240</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a clinical diagnosis of moderate to severe plaque psoriasis for 6 months
             or longer with at least 5% or greater Body Surface Area (BSA) affected with plaque
             psoriasis

          -  Subject must be a candidate for phototherapy and/or systemic therapy

          -  Subject must agree to avoid prolonged exposure to the sun and avoid the use of tanning
             booths or other ultraviolet light sources during the study

          -  Female subject must be either:

               -  post-menopausal (defined as at least 1 year without any menses) prior to
                  Screening, or

               -  premenarchal prior to Screening, or

               -  documented surgically sterile or status post hysterectomy (at least 1 month prior
                  to Screening), or

          -  if of childbearing potential, must have a negative serum pregnancy test at Screening
             and if sexually active must be using highly effective contraception. All sexually
             active subjects will be required to use highly effective contraception consisting of
             two forms of birth control (one of which must be a barrier method) starting at
             Screening and throughout the study period and for 28 days [or 5 five half lives of the
             study drug whichever is longer] after final study drug administration.

          -  Female subject must not be lactating and must not be breastfeeding at Screening or
             during the study period and for 28 days [or 5 five half lives of the study drug
             whichever is longer] after final study drug administration.

          -  Female subject must not donate ova starting at Screening and throughout the study
             period and for 28 days [or 5 five half lives of the study drug whichever is longer]
             after final study drug administration.

          -  Male subject and their female spouse/partners who are sexually active must be using
             highly effective contraception1 consisting of two forms of birth control (one of which
             must be a barrier method) starting at Screening and continue throughout the study
             period and for 28 days [or 5 five half lives of the study drug whichever is longer]
             after final study drug administration.

          -  Male subject must not donate sperm starting at Screening and throughout the study
             period and for at least 28 days [or 5 five half lives of the study drug whichever is
             longer] after final study drug administration.

          -  Highly effective contraception is defined as:

               -  Established use of oral, injected or implanted hormonal methods of contraception.

               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)

               -  Barrier methods of contraception: Condom alone or Occlusive cap (diaphragm or
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

          -  Subject must be willing and able to comply with the study requirements, including
             prohibited concomitant medication restrictions.

          -  Waivers to the inclusion criteria will NOT be allowed.

        Exclusion Criteria:

          -  Subject has non-plaque psoriasis (such as guttate, erythrodermic or pustular
             psoriasis)

          -  Subject has received treatment with systemic, non-biologic psoriasis therapy or other
             systemic immunosuppressant including investigational use of an approved agent within
             the last 30 days or 5 half-lives, whichever is longer, prior to the first dose of
             study drug

          -  Subject has ever been treated with efalizumab (Raptiva®)

          -  Subject has a total B lymphocyte count by flow cytometric determination that is less
             than the lower limit of normal

          -  Subject has a hemoglobin, that are below the lower limit

          -  Subject has a total white count, total lymphocyte count, total neutrophil count or
             total platelet that are below the lower limit

          -  Subject has any of the following lab values:

               -  ALT ≥ 1.5 x upper limit of normal

               -  AST ≥ 1.5 x upper limit of normal

               -  Total bilirubin ≥ 1.5 x upper limit of normal

          -  Subject has previously received ASKP1240 or has participated in a study involving
             ASKP1240

          -  Subject has &gt; 45 body mass index (BMI)

          -  Subject with a positive Tubercle Bacillus (TB) test who has not previously received
             adequate antimicrobial therapy for TB or is currently on, or is planned to start TB
             antimicrobial therapy

          -  Subject has abnormal chest x-ray indicative of acute or chronic lung disease

          -  Subject has uncontrolled intercurrent illness, including, but not limited to ongoing
             or active infection, any clinically significant cardiac disease seizure disorder, or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Subject has a history of any malignancy regardless of the location and the time of
             diagnosis in the last 5 years (including in-situ carcinoma of the cervix, but
             excluding successfully treated non-metastatic basal cell and squamous cell carcinoma)

          -  Subject has received live or live attenuated virus vaccinations within the last 30
             days prior to first dose of study drug

          -  Subject has received treatment with another investigational drug within 30 days or 5
             half-lives; whichever is longer, prior to the initiation of Screening

          -  Subject has a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C
             (HCV) antibody

          -  Subject has a history of a positive test for human immunodeficiency virus (HIV)
             infection

          -  Subject has received treatment with systemic, biologic psoriasis therapy or other
             systemic immunosuppressant including investigational use of an approved agent within
             the last 56 days or 5 half-lives whichever is longer, prior to the first dose of study
             drug

          -  Waivers to the exclusion criteria will NOT be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Specialist Connect</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>Victoria</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durondel C.P. Inc, The Dermatology Clinic</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Lab Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clincial Studies Trust, Ltd.</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research, Tauranga</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research, Wellington</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Psoriasis</keyword>
  <keyword>Severe Psoriasis</keyword>
  <keyword>Skin disease</keyword>
  <keyword>ASKP1240</keyword>
  <keyword>CD40 antigen</keyword>
  <keyword>Anti-CD40 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

